Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xeljanz

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

- PMLiVE

Baxter re-files HyQvia for immunodeficiency in US

Pharma company provides FDA with more data

- PMLiVE

FDA backs new formulation of Noxafil

Merck wins US approval for delayed-release version of anti-infective

- PMLiVE

FDA lifts restrictions on Avandia use

US regulator says GSK’s diabetes drug does not increase heart attack risk

- PMLiVE

BTG rises on FDA approval of varicose vein therapy

Varithena receives green light in US

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

- PMLiVE

New FDA guidance for advertising

Clarifies circumstances when drug names need to be mentioned

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

FDA turns down Forest/Gedeon Richter’s antipsychotic

US regulator wants more information for cariprazine

- PMLiVE

Pfizer extends optimisation campaign

Pharma company supports efforts to ensure public get best out of medicines

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links